An observational study in Diabetes Mellitus, Type 1 and Energy Metabolism, sponsored by Lia Bally. Completed at 1 site in Switzerland. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Lia Bally · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland — 9 open to participants now, 10 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Switzerland.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, this one is the 14th largest by enrollment of the 18 observational ones that give a count, is one of 4 that started in 2025, is one of 18 observational ones, and was the 69th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →9 of the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Switzerland, Canada
Ages 18+
DCB Research AG · Sites in Switzerland
Ages 18–40 · Women only
Sanofi · Sites in Switzerland, United States, Argentina and 17 more countries
Ages 1–25
University of Bern · Sites in Switzerland
Ages 18–65
Pediatric Clinical Research Platform · Sites in Switzerland
Ages 0–25 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 16
First in 1997; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 29 across the 52 interventional studies, 73 across the 18 observational. Of the 55 that completed or were terminated, 6 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 70 have an industry lead sponsor. The 10 most frequent:
Lia Bally is the lead sponsor of 15 studies on the registry; none are open to participants now.
Lia Bally has 3 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
3 of the studies in Diabetes Mellitus, Type 1 with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05594706University Hospital, GenevaAnhydroglucitol in Children With Type 1 Diabetes | 2026-12-31 |
| NCT05791201Vertex Pharmaceuticals IncorporatedA Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | 2027-03-12 |
| NCT06282055DCB Research AGTrajectories in Insulin Sensitivity Across MEnstrual cycleS in Women With Type 1 Diabetes | 2027-09-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 70 studies in Diabetes Mellitus, Type 1 with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The hypothesis is that menstrual cyclicity affects glucose and energy metabolism in women with type 1 diabetes. The rationale of the hypothesis on cycle effects builds on the assumption that fluctuations of female sex hormones across the menstrual cycle cause changes in physiological parameters of glucose metabolism and energy homeostasis and/or lifestyle aspects involved in the regulation of blood glucose and body weight. It is expected that hormone fluctuations affect insulin sensitivity, gastric emptying, eating behaviour and energy expenditure. It is anticipated that insulin sensitivity is highest in the pre-ovulatory phase and lowest in the mid-luteal phase. It is further expected that gastric emptying peaks in the follicular phase, and highest energy expenditure and dietary intake are expected during the mid-luteal phase.
The primary objective of this study is to characterize glucose and energy metabolism throughout the menstrual cycle in natural cycling women with type 1 diabetes. Further objectives are to assess the impact of the menstrual cycle on glucose control and insulin requirements, investigate how fluctuations in sex hormone levels influence glucose and energy metabolism, and quantify both inter- and intra-individual variability in metabolic changes related to the menstrual cycle. Additionally, the study will evaluate whether changes in key physiological components of glucose metabolism and behavioural factors mediate menstrual cycle-related variations in glucose control and insulin requirements.
Eligible participants will be women aged 18-45 years, with a natural menstrual cycle (occurring without medical or hormonal interventions), who have Type 1 Diabetes and are willing to follow study-related procedures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with type 1 diabetes from age 18 to 45 years and a natural menstrual cycle will be followed for 3 consecutive menstrual cycles.
Time in target glucose range
The primary metric for glucose control is the proportion of time with sensor glucose levels in the target range (3.9-10mmol/L, %). Glucose levels will be measured using a continuous glucose monitoring sensor (Dexcom G6 or an equivalent CGM sensor).
Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Algorithm-directed insulin delivery following a standardized meal
The primary insulin metric is the algorithm-directed insulin dose (units) delivered over a 3 hour period following a standardized meal without a manual bolus. Insulin delivery is recorded using the mylife CamAPS FX automated insulin delivery system.
Time frame: The outcome will be measured at each standardized meal assessment, performed during the three key menstrual cycle phases (early-follicular, pre-ovulatory, and mid-luteal),across three menstrual cycles, resulting in a total of nine 3-hour assessment times
Insulin sensitivity
Insulin sensitivity will be estimated continuously throughout the study from sensor glucose and insulin pump data, collected via the mylife CamAPS FX automated insulin delivery system, using mathematical modeling.
Time frame: Continuously over three menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Gastric emptying
This outcome is based in the \[13C\]-acetate breath test. Breath 13CO2 enrichment is analyzed using infrared spectrometry and kinetics parameters are derived using mathematical modelling. The main parameter of interest is T50 (ie., the time until half of the ingested meal was absorbed). This outcome is measured only in a subgroup of 15 participants.
Time frame: The outcome is evaluated at each phase-specific assessment (early follicular, pre-ovulatory, and luteal) for one menstrual cycle.
Total energy expenditure
Total energy expenditure will be quantified using the doubly labelled water method. This outcome is measured only in a subgroup of 15 participants.
Time frame: Continuously over one menstrual cycle. Duration varies depending on individual cycle length, ranging from 20 days to 50 days.
Substrate oxidation
Substrate oxidation (i.e, quantified by the relative contribution of fat oxidation to resting energy expenditure) will be measured by indirect calorimetry in the fasted state (≥8 hours) to provide additional context as a physiological determinant of glucose and energy metabolism. This outcome is measured only in a subgroup of 15 participants.
Time frame: Assessed once at each phase-specific assessment (early follicular, pre-ovulatory, and luteal) for one menstrual cycle
Dietary intake
Total energy intake (kcal/day) will be assessed by recording all meals using an image-based automated food analysis application SNAQ.
Time frame: Measured for 3 days following each phase-specific assessment (early follicular, pre-ovulatory, and luteal) across three menstrual cycles, totaling 27 days over 3 cycles
Physical activity
The number of steps per day, as a component of physical activity, will be measured using the Garmin Venu 3 smartwatch.
Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Postprandial mean glucose
Mean postprandial glucose levels measured using continuous glucose monitoring in the 3 hours following meals. Meal timepoints defined as manual carbohydrate entries in the mylife CamAPS FX automated insulin delivery system. This outcome serves as an additional metric within the overall assessment of glucose control. Additionally, mean postprandial glucose levels will be specifically measured in the 3 hours following the standardized meal assessment using continuous glucose monitoring.
Time frame: The outcome will be evaluated continuously over 3 menstrual cycles (duration varies from 60 days (20-day cycles) to 150 days (50-day cycles)) as well as at each standardized meal assessment, resulting in a total of nine 3-hour assessment times.
Postprandial peak glucose
Peak postprandial glucose levels measured using continuous glucose monitoring in the 3 hours following meals. Meal timepoints defined as manual carbohydrate entries in the mylife CamAPS FX automated insulin delivery system. This outcome serves as an additional metric within the overall assessment of glucose control. Additionally, peak postprandial glucose levels will be specifically measuredin the 3 hours following the standardized meal assessment using continuous glucose monitoring.
Time frame: The outcome will be evaluated continuously over 3 menstrual cycles (duration varies from 60 days (20-day cycles) to 150 days (50-day cycles)) as well as once for each standardized meal assessment (9 values in total).
Proportion of time spent in the hyperglycaemic range
Glucose levels above 10 mmol/L are classified as hyperglycaemic. Glucose levels will be measured using a continuous glucose monitoring (Dexcom G6 system or an equivalent CGM sensor). This outcome serves as an additional metric within the overall assessment of glucose control.
Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles)
Proportion of time spent in hypoglycaemic range
Glucose levels below 3.9 mmol/L are classified as hypoglycaemic. Glucose levels will be measured using continuous glucose monitoring (Dexcom G6 system or an equivalent CGM sensor) This outcome serves as an additional metric within the overall assessment of glucose control.
Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Glucose variability - standard deviation
Glucose variability assessed as the standard deviation (SD) of sensor glucose values measured using continuous glucose monitoring. This outcome provides an additional metric contributing to the assessment of glucose variability and overall glucose control.
Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Glucose variability - coefficient of variation
Glucose variability assessed as the coefficient of variation (CV) of sensor glucose values measured using continuous glucose monitoring data. This outcome provides an additional metric contributing to the assessment of glucose variability and overall glucose control.
Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Glucose variability - mean amplitude of glycaemic excursions
Glucose variability assessed as the mean amplitude of glycaemic excursions (MAGE) derived from continuous glucose monitoring data. This outcome provides an additional metric contributing to the assessment of glucose variability and overall glucose control.
Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Total daily insulin dose
Total daily insulin dose (U/day) will be evaluated using the mylife CamAPS FX automated insulin delivery system, which includes a continuous glucose monitoring sensor (Dexcom G6 or an equivalent CGM sensor for participants already using mylife CamAPS FX with a different sensor), an insulin pump (YpsoPump), and the CamAPS FX application. This outcome serves as an additional measure of individual insulin requirements.
Time frame: Over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Basal insulin
As an additional measure of insulin requirements, the proportion of basal insulin relative to total insulin delivery (%) will be assessed. It will be measured using the mylife CamAPS FX AID system consisting of a continuous glucose monitoring sensor (Dexcom G6 system or an equivalent CGM sensor if they already use the mylife CamAPS FX AID system with a different sensor), the insuline pump (Ypsopump) and the CamAPS FX app.
Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Bolus frequency
Units are (n/day). The outcome is the number of manual boluses entered into the mylife CamAPS FX AID system.
Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Resting energy expenditure
Resting energy expenditure (kcal/day) will be measured by indirect calorimetry in the fasted state (≥8 hours) to provide additional context as a physiological determinant of energy metabolism. This outcome is measured only in a subgroup of 15 participants.
Time frame: Assessed once at each phase-specific assessment (early follicular, pre-ovulatory, and luteal) for one menstrual cycle.
Model-estimated energy intake
Daily energy intake (kcal/day) will be estimated using an energy balance model based on frequently measured body weight and physical activity data, and, where available, energy expenditure assessed using the doubly labeled water methodology. This outcome provides a complementary, model-based estimate of energy intake alongside self-reported dietary intake.
Time frame: Continuously over three menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Proportion of carbohydrate intake
The proportion of carbohydrate intake (% of total energy intake) will be derived from meal records collected using the image-based automated food analysis application (SNAQ), providing complementary information on macronutrient distribution.
Time frame: Measured over 3 days following each phase-specific assessment (early follicular, pre-ovulatory, and luteal) across three menstrual cycles, totaling 27 days from 9 assessments.
Proportion of fat intake
The proportion of fat intake (% of total energy intake) will be derived from meal records collected using the image-based automated food analysis application (SNAQ), providing complementary information on macronutrient distribution.
Time frame: Measured over 3 days following each phase-specific assessment (early follicular, pre-ovulatory, and luteal) across three menstrual cycles, totaling 27 days from 9 assessments.
Proportion of protein intake
The proportion of protein intake (% of total energy intake) will be derived from meal records collected using the image-based automated food analysis application (SNAQ), providing complementary information on macronutrient distribution.
Time frame: Measured over 3 days following each phase-specific assessment (early follicular, pre-ovulatory, and luteal) across three menstrual cycles, totaling 27 days from 9 assessments.
Dietary fiber intake
Dietary fiber intake will be derived from meal records collected using the SNAQ application as an additional component of overall dietary intake assessment.
Time frame: Total intake over 3 days following each phase-specific assessment (early follicular, pre-ovulatory, and luteal) across three menstrual cycles, totaling 27 days from 9 assessments.
Food category distribution
Food category distribution will be derived from meal records collected using the SNAQ application, providing complementary information on dietary patterns within overall dietary intake.
Time frame: Measured continuously at every meal for 3 days following each phase-specific assessment (early follicular, pre-ovulatory, and luteal) across three menstrual cycles, totaling 27 days from 9 assessments.
Activity minutes per day
Active minutes per day will be measured using the Garmin Venu 3 smartwatch as a complementary indicator of physical activity.
Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Body weight
Body weight will be measured using the Garmin Index S2 smart scale to provide additional metabolic context.
Time frame: Measured daily over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Fat mass
Percentage of body fat mass, as a component of body composition, will be measured using the Garmin Index S2 smart scale to provide additional metabolic context.
Time frame: Daily over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Fat-free mass
Percentage of fat-free mass, as a component of body composition, will be measured using the Garmin Index S2 smart scale to provide additional metabolic context.
Time frame: Measured daily over three menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Beta-hydroxybutyrate levels
Beta-hydroxybutyrate levels (mmol/L), will be assessed using the SiBio Ketone Sensor to provide additional metabolic context.
Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Heart rate
Heart rate (bpm), will be assessed using the Garmin Venu 3 smartwatch to provide a broader metabolic context.
Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Heart rate variability
Heart rate variability (High and low frequency components or equivalent time domain indices), will be assessed using the Garmin Venu 3 smartwatch to provide a broader metabolic context and as an indicator of autonomic nervous system activity.
Time frame: Continuously over 3 menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Patient-reported perceived impact
Perceived impact of the menstrual cycle on diabetes control and management will be captured retrospectively at the end of the study using an experience questionnaire.
Time frame: At study completion (after three menstrual cycles).
Patient-reported perceived impact - real-time electronic logs
Perceived impact of the menstrual cycle on diabetes control and management will be captured additionally in real time using electronic logs in a smartphone app. Data are considered supplementary to the experience questionnaire-based assessment.
Time frame: Continuously over three menstrual cycles. Duration varies depending on individual cycle length, ranging from 60 days (20-day cycles) to 150 days (50-day cycles).
Plan to share: Yes — Individual participant data (IPD) will be made available upon reasonable request to the principal investigator.
Supporting information: Study protocol, Analytic code
Time frame: IPD will be made availabe starting 12 month after publication of trial results.
Access criteria: Ethics approval, as applicable under Swiss legislation, will need to be obtained by those requesting the data. Additionally, a data transfer and processing agreement must be in place to ensure compliance with data protection regulations.
Ran from May 2025 to primary completion in Sep 2026, 15 months.
Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's 15 months is below that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lia Bally